Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNT 5505

Next Previous
Drug Profile

SNT 5505

Alternative Names: PXS-5505A; PXS‐5505; SLT-5505; SNT-5505

Latest Information Update: 02 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmaxis
  • Developer Syntara Limited; University of Rochester
  • Class Amines; Antifibrotics; Antineoplastics; Fluorinated hydrocarbons; Quinolones; Small molecules; Sulfones
  • Mechanism of Action Protein lysine 6 oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liver cancer; Myelodysplastic syndromes; Myelofibrosis; Myeloid leukaemia
  • No development reported Fibrosis

Most Recent Events

  • 06 Dec 2025 Updated efficacy and adverse event data from a phase I/IIa trial in Myelofibrosis presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 02 Sep 2025 Phase-I/II clinical trials in Myelodysplastic syndromes in Germany (PO) (CTIS2024-517237-40-00) (EudraCT-2024-517237-40-00)
  • 02 Sep 2025 Phase-I/II clinical trials in Myeloid leukaemia in Germany (PO) (CTIS2024-517237-40-00) (EudraCT-2024-517237-40-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top